October 12, 2013Open Access

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

FGFR2 fusions occur in 13.6% of intrahepatic cholangiocarcinoma. The expression pattern of these fusions in association with sensitivity to FGFR inhibitors warrant a new molecular classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Arai et al. (Sat,) studied this question.

synapsesocial.com/papers/69dac0b5aae38ff6ad8367ea — DOI: https://doi.org/10.1002/hep.26890

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

IRBIT, a Novel Inositol 1,4,5-Trisphosphate (IP3) Receptor-binding Protein, Is Released from the IP3 Receptor upon IP3 Binding to the Receptor· 2003 · 196 citations
Classification, Diagnosis, and Management of Cholangiocarcinoma· 2012 · 303 citations
Cholangiocarcinoma· 2005 · 1,055 citations
Fibroblast growth factor signalling: from development to cancer· 2010 · 2,666 citations
SAM domains: uniform structure, diversity of function· 2003 · 265 citations

Authors

Yasuhito Arai

Hiroshima University

Yasushi Totoki

Osaka City University

Fumie Hosoda

National Cancer Research Institute

Journals

Hepatology

Actions

Institutions

Tokyo National Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider